Anteris Technologies Global Corp. — Capital/Financing Update 2021

Oct 31, 2021

ASX ANNOUNCEMENT

1 November 2021

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 1 November 2021, Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) issued 625,000 new fully paid ordinary shares ( New Shares ) to funds managed or advised by Melbournebased global investor L1 Capital ( Investors ), including L1 Long Short Fund Limited, at $8.00 each raising $5 million.

In addition, Evolution Capital Pty Ltd, acting as lead manager for the placement, was issued 37,500 fully paid ordinary shares ( Lead Manager Shares ) in the Company as partial consideration for facilitating the capital raising.

Details of the securities issued

Class of securities: Fully paid ordinary shares ASX code: AVR Date of the issue: 1 November 2021 Total number of securities issued: 662,500

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act )[1] that:

1. the New Shares and Lead Manager Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act;

3. as at the date of this notice, Anteris advises that it is continuing to prepare for DurAVR[TM] , the Company’s 3D single-piece aortic valve, to be implanted in humans to test the safety and feasibility of DurAVR[TM] ’s THV system on patients with severe aortic stenosis as the Company pursues regulatory approvals in both Europe and the US; and

4. apart from the matters noted above, there is no other ‘excluded information’ of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

1 As modified by ASIC Instrument 21-0248 dated 7 April 2021 which extends the period of 5 days referred to in section 708A(5)(b) of the Corporations Act to 6 days in respect of shares issued by Anteris.

==> picture [95 x 51] intentionally omitted <==

Anteris Technologies Ltd Registered Office: Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR™’s unique 3D singlepiece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Hannah Howlett WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 4 5064 8064 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

==> picture [95 x 51] intentionally omitted <==